Contents
January 2020
Vol 5, Issue 43
Vol 5, Issue 43
Focus
- A new perspective in cancer immunotherapy: PD-1 on myeloid cells takes center stage in orchestrating immune checkpoint blockade
PD-1 mediates antitumor immunity by regulating lineage fate commitment and function of myeloid cells (see the related Research Article by Strauss et al.).
Research Articles
- Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
GSDME-mediated target cell pyroptosis by CAR T cells activates macrophages to release proinflammatory cytokines for CRS.
- Airway brush cells generate cysteinyl leukotrienes through the ATP sensor P2Y2
Aeroallergens and ATP elicit cysteinyl leukotrienes from nasal brush cells through the purinergic receptor P2Y2.
- BATF acts as an essential regulator of IL-25–responsive migratory ILC2 cell fate and function
BATF-deficient mice lack iILC2 cells, which serve as an important early source of IL-4/IL-13 upon helminth infection.
- Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow, giving rise to serological memory
Long-lived IgE+ plasma cells in the bone marrow confer IgE memory and produce allergen-specific IgE that can drive anaphylaxis.
- Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
PD-1 ablation regulates metabolism-driven lineage fate commitment of myeloid progenitors and differentiation of effector myeloid cells (see the related Focus by Rudd).
- Human T cell response to CD1a and contact dermatitis allergens in botanical extracts and commercial skin care products
CD1a, an abundant lipid antigen–presenting molecule in human skin, mediates T cell responses to small contact allergens.
Review
- Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity
Preserving a homeostatic balance with resident microbial communities of the oropharynx depends on a measured dose of type 17 immunity.
Editors' Choice
- Cis interactions make immune checkpoint blockade more trans-parent
PD-L1:CD80 cis-heterodimer formation preferentially blocks CTLA-4 trans-signaling while allowing CD28-mediated effector T cell activation.
- “B”-fing up immune-mediated diseases
Extensive characterization of B cell receptor repertoires across six immune-mediated diseases reveals novel insights into disease pathogenesis.
Erratum
About The Cover
ONLINE COVER Turning Anti–PD-1 on Its Head. This month's cover illustration is a 3D rendition of pembrolizumab, one of several therapeutic monoclonal antibodies against human PD-1 being used for cancer immunotherapy. Based on results with a new conditional allele of the Pdcd1 gene in mice, Strauss et al. report that PD-1 expression on both myeloid and T cells is relevant to the immune stimulatory effects of anti–PD-1. A Focus commentary by Rudd discusses the findings of Strauss et al. The illustration was created with NGL Viewer using x-ray crystallography data deposited in the RCSB Protein Data Bank. [CREDIT: PDB 5DK3]
